Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Medivir AB ( (SE:MVIR) ) is now available.
Medivir AB announced the departure of its CFO, Magnus Christensen, who will take on a similar role at Cinclus Pharma. Christensen, who has been with Medivir since 2019 and briefly served as interim CEO, will remain during a transition period to ensure a smooth handover. The company has started the recruitment process for a new CFO. This change in leadership comes as Medivir continues to focus on its core mission of developing innovative cancer treatments, with potential implications for its strategic direction and stakeholder relations.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company specializing in the development of innovative cancer treatments, particularly in areas with high unmet medical needs. The company focuses on creating drug candidates for indications where current therapies are limited or nonexistent, aiming to offer significant improvements for patients. Medivir’s primary drug candidate is fostroxacitabine bralpamide (fostrox), designed to target liver cancer cells selectively while minimizing side effects. The company operates through collaborations and partnerships and is listed on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 902,595
Technical Sentiment Signal: Sell
Current Market Cap: SEK42.62M
For a thorough assessment of MVIR stock, go to TipRanks’ Stock Analysis page.